Effects of cisplatin on different haemopoietic progenitor cells in mice. by Nowrousian, M. R. & Schmidt, C. G.
Br. J. Cancer (1982) 46, 397
EFFECTS OF CISPLATIN ON DIFFERENT HAEMOPOIETIC
PROGENITOR CELLS IN MICE
M. R. NOWROUSIAN AND C. G. SCHMIDT
From the West German Tumour Center, University of Essen, Department of Internal Medicine
(Cancer Research), Essen, F.R.G.
Received 5 October 1981 Accepted 29 April 1982
Summary.-The effects of Cisplatin on marrow haemopoietic progenitor cells, WBC
and RBC were measured and compared in F1 (CBA x C57BL) female mice. Dose/
survival curves of Cisplatin for CFU-S, CFU-C and BFU-E were found to be simply
exponential, indicating that the effect of the drug has no cell-cycle dependency.
BFU-E also appeared significantly (P<0001) more sensitive to Cisplatin than
CFU-S and CFU-C. After a single dose of 12 mg/kg of Cisplatin, WBC, MNC
and CFU-E were seen to be markedly less reduced and to recover much earlier than
CFU-C, and particularly BFU-E and CFU-S. Results suggest that the drug is more
toxic for earlier haemopoietic progenitor cells than for the more mature cells, and
that the latter are not reliable parameters for complete haemopoietic recovery in
mice after treatment with this agent. In the animals treated, there was also a subse-
quent significant decrease of the RBC count, accompanied by a marked increase of
the marrow CFU-E concentration. Possible underlying mechanisms (e.g. alterations
of RBC after exposure to Cisplatin) were discussed.
CISPLATIN (cis-diamminedichloro-
platinum II) has been shown to be an
effective antineoplastic agent in experi-
mental animals and in man (Prestayko et
al., 1979). In earlier studies, the major
dose-limiting factor in the clinical use of
this agent was reported to be the dose-
related and cumulative renal toxicity
(Krakoff, 1979; Talley et al., 1973). The
myelotoxicity ofCisplatin became increas-
ingly evident after high doses of the drug
were given with nephrotoxicity reduced by
hydration and diuretics (Prestayko et al.,
1979; Chary et al., 1977). Recently, several
investigators have reported severe myelo-
suppresion in patients treated with Cis-
platin or chemotherapy combinations con-
taining this agent (von Hoff et al., 1979;
Kuzur & Greco, 1980). The drug was found
to induce not only leucocytopenia and
thrombocytopenia, but also severe anae-
mia when given repeatedly, a phenomenon
which is unusual in patient treated with
combinations containing cytotoxic agents
other than Cisplatin (Rossof et al., 1972;
von Hoff et al., 1979; Kuzur & Greco,
1980). The anaemia was considered to be
secondary to changes in erythropoiesis,
and in some cases to haemolysis (Kuzur &
Greco, 1980; Rothmann & Weick, 1981;
Getaz et al., 1980; Levi et al., 1981; van
Nguyen & Jaffe, 1981). However, the
mechanisms responsible have not yet been
thoroughly investigated. Moreover, few
studies have been carried out to evaluate
the effects of Cisplatin on haemopoiesis
and particularly on haemopoietic stem
cells. The drug has been shown to have a
dose-related and cumulative toxicity for
CFU-S and CFU-C in mice (Jenkins et al.,
1981; Dumenil et al., in press) and to be
more toxic to murine CFU-C than to
human cells (Ogawa et al., 1975).
The aim of the present study was to
Correspondence to: Dr AI. R. Nowrousian, Westdeutsches Tumorzentrum, Innere Universitatsklinik und
Poliklinik (Tumorforschlung), Hufelandstrasse 55, 4300 Essen, F.R.G.M. R. NOWROUSIAN AND C. G. SCHMIDT
define the sensitivity of different haemo-
poietic stem cells to Cisplatin in mice, and
to investigate the recovery of cells after a
single dose ofthe agent equivalent in mice
to doses usually given in man.
MATERIALS AND METHODS
Animals anddrugadmini8tration.-F1 (CBA
x C57BL) female mice, 10-12 weeks of age
and weighing 20-25 g, were used, both for
Cisplatin treatment and as recipients for
CFU-S assays. Cisplatin (Haereus, Hanau,
F.R.G.) was appropriately dissolved in
0 5 ml sterile water and given i.p. Survival of
cells was determined 24 h after injection of
various drug doses, and recovery of cells
after a single dose of 12 mg/kg of Cisplatin.
The latter lies between the LD10 and the
LD50 for mice (Penta et at., 1979) and using
the conversion factor ofFreireich et al. (1966)
it is comparable to a single dose of 70 mg
given to a human weighing 70 kg. Single-cell
suspensions were prepared from flushed
femoral marrow of 3 mice/group/point, and
blood samples for individual WBC and RBC
counts were obtained by severing the axillary
vessels.
CFU-S, CFU-C, BFU-E and CFU-E
assays.-CFU-S was assayed by the method
of Till & McCulloch (1961). Recipient mice,
at least 10 mice/point/group, were exposed to
7-5 Gytotal-body irradiation (X-ray machine,
rate 1-43 Gy/min, focal distance 40 cm) before
injection of 4 x 104 nucleated cells from the
marrow (MNC). Macroscopic surface colonies
in the spleens were counted 9 days later.
CFU-C were assayed according to the method
of Bradley & Metcalf (1966) as modified by
Iscove (1972). MNC 105 were cultured in 1 ml
a-medium containing 0.8% methylcellulose,
20% horse serum and 20% mouse heart-
conditioned medium (Byrne et at., 1978).
BFU-E and CFU-E were assayed by the
method of Iscove & Sieber (1975). MNC
(2 x 105) were cultured in 1 ml Iscove's modi-
fied Dulbecco's medium containing 08%
methylcellulose, 1% bovine serum albumin,
15% foetal calf serum, 15% horse serum,
10-4M 2-mercaptoethanol and sheep-plasma
erythropoietin (2 U for BFU-E, 0-2 U for
CFU-E, Connaught). All cultures were set up
in triplicates and incubated at 37°C in a
humified atmosphere with 5% CO2 in air.
CFU-C were scored on Day 7, BFU-E on Day
9 and CFU-E on Day 2 ofincubation. BFU-E
and CFU-E colonies were stained using an
improved benzidine staining technique
(Gallicchio & Murphy, 1979).
Statistical analysis.-Linear regression was
fitted according tothemethodofleast squares.
Significance of difference between the slopes
of dose/survival curves was tested by com-
paring the regression coefficients using the t
test. Recovery data were analysed on differ-
ence between the treated and control groups
using both the t test and Mann-Whitney test.
RESULTS
The marrow nucleated cell count
decreased progressively up to 75% of the
control values with increasing doses of
Cisplatin between 0'5 and 3 mg/kg. There-
after, no further significant reduction was
observed with higher doses.
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FIG. l.-Dose/survival curves of CFU-C
(--*), CFU-S (@-.-*) and BFU-E
(A *--A--) toCisplatin inmice. Cell survival
was determined 24 h after i.p. injection of
the drug. Data represent the means+s.e.
from 3-8 separate experiments. The slope
of the BFU-E curve (-0.41) differs signifi-
cantly (P <0001) from those of CFU-C
(-0.22) and CFU-S (-0 25).
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FIG. 2. Serial changes in RBC, WBC and to % ofcontrol values. Vertical bars signify
MNC in mice after a single i.p. injection of s.e. of 3-8 separate experiments. Shaded
12 mg/kg ofCisplatin. Data were converted zones represent the means + s.e. of all con-
to % ofcontrol values. Vertical bars signify trol values for CFU-S (2809 + 66/femur)
s.e. of 3-8 separate experiments. Shaded and CFU-C (14622 + 982/femur) obtained
zones represent the means + s.e. of all con- in this study.
trol values for RBC (8.23 + 0-1 x 1012/1),
WBC (4983+574x 109/1) and MNC (11-84
+ 0-16 x 106/femur) obtained in this study. significantly (P < 0.05) below normal and
reached 87% of the control values by Day
The surviving fractions of CFU-S, 23. The cells, however, did not show any
CFU-C and BFU-E showed a continuous apparent changes in their size, shape or
exponential decrease with increasing drug staining characteristics. The MNC had
doses above 1 mg/kg (Fig. 1). BFU-E, in their nadir on Day 3 after treatment at
addition, appeared to be significantly 65% ofthe control values; the cell number
(P < 0001) more sensitive to Cisplatin returned to normal by Day 8.
than CFU-S and CFU-C. The CFU-S number dropped rapidly to
After a single dose of 12 mg/kg of 5% of the control value on Day 1 after
Cisplatin, the WBC count showed a drug administration (Fig. 3). Thereafter,
decrease up to 53% of the control values the CFU-S compartment size increased
during the first 3 days, followed by a progressively to reach subnormal levels by
return to normal by Day 5 (Fig. 2). The Day 15, and remained subnormal as long
RBC count remained unchanged for the as the cells were studied. The CFU-C were
first 2 days after drug application, but reduced up to 6% of the control value
increased significantly (P<0.05) above during the first 2 days aftertreatment; the
normal levels by Days 3-5 and returned to cell concentration then startedtorise, with
normal by Day 8. During this period the a recovery ofthe cells being completed on
animals frequently developed gastroenter- Day 15.
itis and loss ofweight. The increase ofthe The BFU-E had their nadir on Day 1
RBC count might therefore be, at least aftertreatment, where 0 85% ofthe control
partially, due to dehydration. From Day value was achieved (Fig. 4). Thereafter,
10, the RBC number decreased slowly but the cells began to recover, but their
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FIG. 4. Recovery of marrow CFU-E and
BFU-E in mice after a single i.p. injection
of 12 mg/kg of Cisplatin. Data were con-
verted to % of control values. Vertical bars
signify the s.e. of 3-8 separate experiments.
Shaded zones represent the means + s.e. of
all control values for CFU-E (10510 +
414/femur) and BFU-E (1031 + 37/femur)
obtained in this study.
recovery was more delayed than that of
CFU-S and CFU-C, since subnormal levels
were not achieved before Day 17. The
CFU-E showed the least degree of suppres-
sion and the most rapid recovery in
comparison to the other cell types. From
Day 10, concomitant with the decrease of
the RBC count, the CFU-E number
increased significantly (P < 0.05) above
normal levels and reached 167 % ofnormal
by Day 23.
DISCUSSION
The exponential dose/survival curves
for CFU-S, CFU-C and BFU-E indicate
that the effect ofCisplatin has no cell-cycle
dependency. This finding agrees with the
observations suggesting a similar toxicity
of Cisplatin for CFU-C both in normal and
regenerating marrow and on cultured
human lymphoma cells in different stages
of the cell cycle (Ogawa et al., 1975;
Drewinko et al., 1973). The differential
sensitivity ofthe cells to Cisplatin has to be
considered valid only for the experimental
conditions studied, since the slopes of
dose/survival curves could change with
variations in the interval between the drug
administration and the assay of stem cells
(van Putten et al., 1972). Additionally, the
different response ofBFU-E and CFU-C to
Cisplatin might be due to the different
maturation stages of these cells and it
could be that earlier congeners of CFU-C
were similarly sensitive as are BFU-E.
The more delayed recovery of CFU-S,
BFU-E and CFU-C by comparison to
MNC andWBC, suggest that the latter are
not reliable parameters for complete
haemopoietic recovery in mice after treat-
ment with Cisplatin. Ifthe same were true
in humans, these indices, usually con-
sidered to be predictive for marrow
toxicity of cytotoxic agents, could not be
used for the evaluation ofthe true effect of
Cisplatin on marrow function.
The recovery pattern of MNC and
CFU-S after a single dose of 12 mg/kg of
Cisplatin in mice is approximately com-
parable to that seen in the same animal
species after exposure to 3-5 Gy whole-
body irradiation (Valeriote et al., 1968;
Guzman & Lajtha, 1970). Additionally,
the effects of Cisplatin on haemopoietic
precursor cells resemble those of agents
such as Busulphan and 1-bis(2-chloro-
ethyl)-l-nitrosourea (BCNU), which have
been shown to be more toxic to the earlier
progenitor cells than to the more mature
cells (Botnick et al., 1981).
The toxicity of Cisplatin for CFU-S and
CFU-C has been reported to be dose-
related and cumulative (Jenkins et al.,
1981; Dumenil et al., in press). Considering
this and our data, similar toxicities were
possible for BFU-E, and these toxic effects
could increase more rapidly with higher
drug doses than that for CFU-S and
particularly CFU-C. The question there-
fore arises whether the pronounced Cis-
platin toxicity for BFU-E could be the
cause of the anaemia induced by this
agent. Such a preferential BFU-E depres-
sion has been reported from a single
patient studied (Rothmann & Weick,
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1981). However, the haemopoietic effects
of Cisplatin might be different in mouse
and man, as reported from in vitro studies
on CFU-C (Ogawa et al., 1975). Further
investigations are therefore needed to
clarify the sensitivity of different haemo-
poetic stem cells to Cisplatin in man, and
to evaluate the recovery of cells after
exposure to repeated doses.
The more prominent anaemia could also
be due to different in vivo maturation
times of erythroid and granulocytic pro-
genitor cells. For example, it might be that
if both cell populations were suppressed
equally by Cisplatin, the smaller number
of cells involved in erythropoiesis per unit
time would eventually lead to a more
pronounced anaemia than granulocyto-
penia. In Cisplatin-treated mice, however,
the anaemia was accompanied by a
marked increase ofmarrow CFU-E, indica-
ting an appropriate response of the
erythropoietic system, despite the pro-
tracted BFU-E recovery. The latter might
therefore be a result of the need for an
enhanced production of mature cells, and
is compatible with the observation made
in anaemic mice, in which an increase of
CFU-E was associated with a decrease of
BFU-E (Hara & Ogawa, 1977). However,
a delay in BFU-E recovery does not seem
to be the cause of anaemia where normal
or raised numbers of CFU-E are present.
Although a high incidence of CFU-E has
been shown to be not always reflected in
effective production ofmature cells (Testa,
1979; Pesch]e et al., 1980), italso seems less
likely that the reduced RBC count was a
result of CFU-E maturation disturbances.
Alternatively, the RBC number could be
depressed by haemolysis. Haemolytic
anaemia has been reported in patients
treated repeatedly with Cisplatin (Getaz et
al., 1980; Levi et al., 1981; van Nguyen &
Jaffe, 1981). The haemolysis was suggested
as induced by antibodies reacting with Cis-
platin-RBC-membrane complexes (Getaz
et al., 1980). Such an antibody-mediated
haemolysis seems unlikely in our experi-
ments, because of the single dose of the
agent given, but other mechanisms (e.g.
toxic effects of Cisplatin on RBC them-
selves) would also be able to induce a
shortened cell survival,leading toanaemia.
Therefore, appropriate studies concerning
possible alterations of RBC after exposure
to Cisplatin could be of value.
This work was supported by a grant from the
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